# A Multicenter, Randomized, Placebo-Controlled, Double-Blinded, Phase I Trial to Evaluate the Safety and Immunogenicity of Live Recombinant Canarypox ALVAC-HIV vCP205 Combined With GM-CSF in Healthy, HIV-1 Uninfected Volunteers

> **NCT00001090** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 36 (—)

## Conditions studied

- HIV Infections

## Interventions

- **BIOLOGICAL:** APL 400-047
- **BIOLOGICAL:** ALVAC-HIV MN120TMG (vCP205)
- **DRUG:** Sargramostim

## Key facts

- **NCT ID:** NCT00001090
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** 1999-10
- **Target enrollment:** 36 (—)
- **Last updated:** 2021-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00001090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00001090, "A Multicenter, Randomized, Placebo-Controlled, Double-Blinded, Phase I Trial to Evaluate the Safety and Immunogenicity of Live Recombinant Canarypox ALVAC-HIV vCP205 Combined With GM-CSF in Healthy, HIV-1 Uninfected Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00001090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*